BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 109 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $372,879 | -29.7% | 147,383 | +85.2% | 0.00% | – |
| Q2 2023 | $530,136 | +28310.3% | 79,600 | -20.4% | 0.00% | -100.0% |
| Q1 2023 | $1,866 | -99.9% | 100,000 | -47.0% | 0.00% | -50.0% |
| Q2 2022 | $2,489,000 | +514.6% | 188,548 | +872.6% | 0.00% | – |
| Q1 2022 | $405,000 | +3.6% | 19,385 | +0.7% | 0.00% | – |
| Q4 2021 | $391,000 | -37.9% | 19,250 | +31.9% | 0.00% | – |
| Q1 2021 | $630,000 | -77.7% | 14,597 | -76.1% | 0.00% | -100.0% |
| Q4 2020 | $2,825,000 | -21.6% | 61,145 | -26.4% | 0.00% | -50.0% |
| Q3 2020 | $3,604,000 | +105.0% | 83,120 | +150.7% | 0.00% | +100.0% |
| Q2 2020 | $1,758,000 | +1284.3% | 33,161 | +157.7% | 0.00% | – |
| Q1 2019 | $127,000 | -69.8% | 12,869 | -71.9% | 0.00% | -100.0% |
| Q2 2018 | $421,000 | +33.2% | 45,796 | +48.3% | 0.00% | – |
| Q1 2018 | $316,000 | – | 30,889 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| APIS CAPITAL ADVISORS, LLC | 40,000 | $836,000 | 1.01% |
| ACT CAPITAL MANAGEMENT, LLC | 20,000 | $418,000 | 0.44% |
| Knoll Capital Management, LLC | 20,000 | $418,000 | 0.26% |
| Artemis Investment Management LLP | 1,428,228 | $29,855,000 | 0.24% |
| Rubric Capital Management LP | 268,528 | $5,615,000 | 0.20% |
| Virtus ETF Advisers LLC | 7,713 | $161,000 | 0.07% |
| BOOTHBAY FUND MANAGEMENT, LLC | 107,700 | $2,252,000 | 0.05% |
| PDT Partners, LLC | 28,031 | $586,000 | 0.05% |
| AllSquare Wealth Management LLC | 3,162 | $66,000 | 0.04% |
| Hennion & Walsh Asset Management, Inc. | 35,221 | $736,000 | 0.04% |